Improving antithrombotic management in patients with atrial fibrillation: Current status and perspectives

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 6, 2009, Pages 527-542

  Levi, Marcel ^a   Hobbs, F D Richard ^b   Jacobson, Alan K ^c   Pisters, Ron ^d   Prisco, Domenico ^e   Bernardo, Artur ^f   Haas, Markus ^g   Heidrich, Jens ^h   Rosenberg, Matt ⁱ   Nielsen, Jørn Dalsgaard ^j   Wuillemin, Walter A ^k  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f Klinik Gais   (Switzerland)

^g St Hedwig Klinik GmbH   (Germany)

^h Laboratory Dr von Froreich   (Germany)

ⁱ General Practitioner   (United States)

^j GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^k UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; Cerebrovascular thrombosis; Coumadin; Thromboembolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; WARFARIN;

ANTICOAGULANT THERAPY; AWARENESS; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CARDIOLOGIST; CLINICAL PRACTICE; CLINICAL TRIAL; CONSENSUS; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; EDUCATION; EUROPE; HEALTH CENTER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTERPERSONAL COMMUNICATION; LABORATORY; MEDICAL SPECIALIST; OUTPATIENT DEPARTMENT; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK; RISK FACTOR; RISK REDUCTION; SELF CARE; STROKE; UNITED STATES;

ANTICOAGULANTS; ATRIAL FIBRILLATION; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STROKE;

EID: 70449333046     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1240013     Document Type: Review

References (117)

1. Fuster V, Rydén L E., Cannom D S. et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines European Society of Cardiology Committee for Practice Guidelines European Heart Rhythm Association Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 114 (7) e257-e354
2. Hylek E M., Go A S., Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003 349 (11) 1019-1026
3. Go A S., Hylek E M., Phillips K A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001 285 (18) 2370-2375
4. Kannel W B., Benjamin E J. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008 92 (1) 17-40 ix
5. Feinberg W M., Blackshear J L., Laupacis A, Kronmal R, Hart R G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995 155 (5) 469-473
6. Miyasaka Y, Barnes M E., Gersh B J. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006 114 (2) 119-125
7. WHO Monica Study. Decision resources. Available at: www.klt.Fi/monica
8. Statistisches Bundesamt. 2007 Available at: www.destatis.de
9. Davies M, Hobbs F, Davis R et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001 358 (9280) 439-444
10. Heeringa J, van der Kuip D A., Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006 27 (8) 949-953
11. Di Carlo A, Baldereschi M, Gandolfo C et al, ILSA Working Group The Italian Longitudinal Study on Aging. Stroke in an elderly population: incidence and impact on survival and daily function. Cerebrovasc Dis 2003 16 (2) 141-150
12. Filippi A, Bettoncelli G, Zaninelli A. Detected atrial fibrillation in north Italy: rates, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis. Fam Pract 2000 17 (4) 337-339
13. National Center of Epidemiology Surveillance and Health Promotion, Italian Institute of Health. The Italian Cardiovascular Epidemiological Observatory. Ital Heart J 2004 5 (suppl 3) 29S-92S
14. Nieuwlaat R, Capucci A, Camm A J. et al, European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005 26 (22) 2422-2434
15. Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen G B., Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004 94 (7) 889-894
16. Wolf P A., Abbott R D., Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 22 (8) 983-988
17. Page R L., Tilsch T W., Connolly S J. et al, Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or silent atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation 2003 107 (8) 1141-1145
18. Kerr C, Boone J, Connolly S et al. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J 1996 17 (suppl C) 48-51
19. American Heart Association. Heart disease and stroke statistics. Update. 2008. Available at: www.americanheart.org/presenter.jhtml
20. Dulli D A., Stanko H, Levine R L. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003 22 (2) 118-123
21. Lin H J., Wolf P A., Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996 27 (10) 1760-1764
22. Kannel W B., Abbott R D., Savage D D., McNamara P M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982 306 (17) 1018-1022
23. Vidaillet H, Granada J F., Chyou P H. et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002 113 (5) 365-370
24. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 (3, suppl) 204S-233S (Pubitemid 39297955)
25. White H D., Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007 167 (3) 239-245
26. Go A S., Hylek E M., Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003 290 (20) 2685-2692
27. Hart R G., Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999 131 (7) 492-501
28. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994 154 (13) 1449-1457
29. Hart R G., Pearce L A., Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007 146 (12) 857-867
30. Aguilar M I., Hart R, Pearce L A. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007 (3) CD006186
31. van Walraven C, Hart R G., Singer D E. et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002 288 (19) 2441-2448
32. Petersen P, Boysen G, Godtfredsen J, Andersen E D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989 1 (8631) 175-179
33. Gulløv A L., Koefoed B G., Petersen P et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998 158 (14) 1513-1521
34. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994 343 (8899) 687-691
35. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993 342 (8882) 1255-1262
36. Rash A, Downes T, Portner R, Yeo W W., Morgan N, Channer K S. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007 36 (2) 151-156
37. Healey J S., Hart R G., Pogue J et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008 39 (5) 1482-1486
38. Hu D Y., Zhang H P., Sun Y H., Jiang L Q., Antithrombotic Therapy in Atrial Fibrillation Study Group. The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2006 34 (4) 295-298
39. Hellemons B S., Langenberg M, Lodder J et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999 319 (7215) 958-964
40. Pérez-Gómez F, Alegría E, Berjón J et al, NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004 44 (8) 1557-1566
41. Morocutti C, Amabile G, Fattapposta F et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale). Investigators. Stroke 1997 28 1015-1021
42. Mant J, Hobbs F D., Fletcher K et al, BAFTA investigators Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007 370 (9586) 493-503 (Pubitemid 47212371)
43. Atwood J E., Albers G W. Anticoagulation and atrial fibrillation. Herz 1993 18 (1) 27-38
44. Fang M C., Go A S., Chang Y et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007 120 (8) 700-705
45. Levi M, Hovingh G K., Cannegieter S C., Vermeulen M, Büller H R., Rosendaal F R. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008 111 (9) 4471-4476
46. van Walraven C, Hart R G., Singer D E., Koudstaal P J., Connolly S. Oral anticoagulants vs. aspirin for stroke prevention in patients with non-valvular atrial fibrillation: the verdict is in. Card Electrophysiol Rev 2003 7 (4) 374-378
47. Hylek E M., Evans-Molina C, Shea C, Henault L E., Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007 115 (21) 2689-2696
48. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London, United Kingdom Royal College of Physicians 2006
49. Albers G W., Dalen J E., Laupacis A, Manning W J., Petersen P, Singer D E. Antithrombotic therapy in atrial fibrillation. Chest 2001 119 (1, suppl) 194S-206S
50. Fumeaux T, Cornuz J, Polikar R et al. Guidelines for the clinical management of atrial fibrillation: a practical perspective. Swiss Med Wkly 2004 134 (1718) 235-247
51. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008 39 (6) 1901-1910
52. Hart R G., Halperin J L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999 131 (9) 688-695
53. Gage B F., Waterman A D., Shannon W, Boechler M, Rich M W., Radford M J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001 285 (22) 2864-2870
54. Hylek E M., Singer D E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994 120 (11) 897-902
55. Fihn S D., Callahan C M., Martin D C., McDonell M B., Henikoff J G., White R H., The National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996 124 (11) 970-979
56. Hart R G., Boop B S., Anderson D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995 26 (8) 1471-1477
57. Hart R G., Aguilar M I. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis 2008 25 (1) 26-32
58. Levine M N., Raskob G, Beyth R J., Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 (3, suppl) 287S-310S (Pubitemid 39297958)
59. Hylek E M., D'Antonio J, Evans-Molina C, Shea C, Henault L E., Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006 37 (4) 1075-1080
60. Fuster V, Rydén L E., Asinger R W. et al, American College of Cardiology American Heart Association European Society of Cardiology North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001 22 (20) 1852-1923 (Pubitemid 33061598)
61. Hart R G., Benavente O, Pearce L A. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 1999 9 (4) 215-217
62. Hart R G., Bhatt D L., Hacke W et al, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis 2008 25 (4) 344-347
63. Biblo L A., Yuan Z, Quan K J., Mackall J A., Rimm A A. Risk of stroke in patients with atrial flutter. Am J Cardiol 2001 87 (3) 346-349, A9
64. Fang M C., Chang Y, Hylek E M. et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004 141 (10) 745-752
65. Hylek E M., Skates S J., Sheehan M A., Singer D E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996 335 (8) 540-546
66. Nieuwlaat R, Olsson S B., Lip G Y. et al, Euro Heart Survey Investigators The Euro Heart Survey on Atrial Fibrillation. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. Am Heart J 2007 153 (6) 1006-1012
67. Ang S Y., Peterson G M., Friesen W T., Vial J H. Review of antithrombotic drug usage in atrial fibrillation. J Clin Pharm Ther 1998 23 (2) 97-106
68. Paciaroni M, Agnelli G, Caso V et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost 2005 3 (6) 1218-1223
69. Ferro D, Loffredo L, Polimeni L, Violi F. Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2007 2 (1) 24-28
70. Zehnder B S., Schaer B A., Jeker U, Cron T A., Osswald S. Atrial fibrillation: estimated excess rate of stroke due to lacking adherence to guidelines. Swiss Med Wkly 2006 136 (4748) 757-760
71. Beyth R J., Antani M R., Covinsky K E. et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996 11 (12) 721-728
72. Chang H J., Bell J R., Deroo D B., Kirk J W., Wasson J H. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch Intern Med 1990 150 (1) 83-86
73. Partington S L., Abid S, Teo K, Oczkowski W, O'Donnell M J. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res 2007 120 (5) 663-669
74. Choudhry N K., Anderson G M., Laupacis A, Ross-Degnan D, Normand S L., Soumerai S B. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006 332 (7534) 141-145
75. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physicians. Stroke 2008 39 (1) 227-230
76. Dinh T, Nieuwlaat R, Tieleman R G. et al. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The NetherlandsThe EXAMINE-AF study. A questionnaire survey. Int J Clin Pract 2007 61 (1) 24-31
77. Deplanque D, Leys D, Parnetti L et al, SAFE II Investigators. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004 57 (6) 798-806
78. Hasenkamp J M., Sygehus S. Living with anticoagulants. Paper presented at: World Congress of Cardiology 2006 Barcelona, Spain
79. Lip G Y., Golding D J., Nazir M, Beevers D G., Child D L., Fletcher R I. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997 47 (418) 285-289
80. Kimmel S E., Chen Z, Price M et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007 167 (3) 229-235
81. Nieuwlaat R, Capucci A, Lip G Y. et al, Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006 27 (24) 3018-3026
82. Arnsten J H., Gelfand J M., Singer D E. Determinants of compliance with anticoagulation: a case-control study. Am J Med 1997 103 (1) 11-17
83. Lane D A., Ponsford J, Shelley A, Sirpal A, Lip G Y. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006 110 (3) 354-358
84. Wofford J L., Wells M D., Singh S. Best strategies for patient education about anticoagulation with warfarin: a systematic review. BMC Health Serv Res 2008 8 40
85. Sawicki P T., Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 1999 281 (2) 145-150
86. Wilson F L., Racine E, Tekieli V, Williams B. Literacy, readability and cultural barriers: critical factors to consider when educating older African Americans about anticoagulation therapy. J Clin Nurs 2003 12 (2) 275-282
87. Reynolds M W., Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004 126 (6) 1938-1945
88. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991 84 (2) 527-539
89. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990 323 (22) 1505-1511
90. Connolly S J., Laupacis A, Gent M, Roberts R S., Cairns J A., Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991 18 (2) 349-355
91. Ezekowitz M D., Bridgers S L., James K E. et al, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992 327 (20) 1406-1412
92. Hirsh J, Dalen J E., Deykin D, Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1992 102 (4, suppl) 312S-326S
93. Bajpai A, Savelieva I, Camm A J. Epidemiology and economic burden of atrial fibrillation. US Cardiovasc Dis 2007 1 14-17
94. Wattigney W A., Mensah G A., Croft J B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003 108 (6) 711-716
95. Stewart S, Murphy N F., Murphy N, Walker A, McGuire A, McMurray J J. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004 90 (3) 286-292
96. Le Heuzey J Y., Paziaud O, Piot O et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004 147 (1) 121-126
97. Coyne K S., Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006 9 (5) 348-356
98. Szucs T D., Bramkamp M. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. J Thromb Haemost 2006 4 (6) 1180-1185
99. Jones M, McEwan P, Morgan C L., Peters J R., Goodfellow J, Currie C J. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005 91 (4) 472-477
100. Regier D A., Sunderji R, Lynd L D., Gin K, Marra C A. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 2006 174 (13) 1847-1852
101. Caro J J. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 2004 10 (14, suppl) S451-S458 discussion S458-S461
102. van Geest-Daalderop J H., Hutten B A., Péquériaux N C., Haas F J., Levi M, Sturk A. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose. Thromb Haemost 2007 98 (4) 738-746
103. Phillips K W., Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther 2008 6 (1) 57-70
104. Bernardo A, Völler H. Arbeitsgemeinschaft Selbstkontrolle der Antikoagulation (ASA) [Guidelines for coagulation self-management]. Dtsch Med Wochenschr 2001 126 (12) 346-351
105. Ansell J, Jacobson A, Levy J, Völler H, Hasenkam J M., International Self-Monitoring Association for Oral Anticoagulation. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005 99 (1) 37-45
106. Fihn S D., McDonell M B., Vermes D et al, National Consortium of Anticoagulation Clinics. A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. J Gen Intern Med 1994 9 (3) 131-139
107. Fitzmaurice D A., Hobbs F D., Delaney B C., Wilson S, McManus R. Review of computerized decision support systems for oral anticoagulation management. Br J Haematol 1998 102 (4) 907-909
108. Fitzmaurice D A., Hobbs F D., Murray E T., Holder R L., Allan T F., Rose P E. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med 2000 160 (15) 2343-2348
109. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori A G. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001 86 (10) 1060-1070
110. Ansell J E. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management. Semin Vasc Med 2003 3 (3) 261-270
111. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007 23 (2) 83-91
112. Nichol M B., Knight T K., Dow T et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008 42 (1) 62-70
113. Cromheecke M E., Levi M, Colly L P. et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000 356 (9224) 97-102
114. Völler H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). Z Kardiol 2005 94 (3) 182-186
115. Heneghan C, Alonso-Coello P, Garcia-Alamino J M., Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006 367 (9508) 404-411 (Pubitemid 43184260)
116. Menéndez-Jándula B, Souto J C., Oliver A et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005 142 (1) 1-10
117. Matchar D B., Jacobson A K., Edson R G. et al. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481the Home INR Study (THINRS). J Thromb Thrombolysis 2005 19 (3) 163-172